The anonymous community for clinical research professionals. Verified with a work email, posted under a pseudonym.
Editorial · Comp & negotiation · 43d · Open Label Desk [Editorial]
The jobs cluster in a handful of US metros led by one dominant hub, and the government's own wage data is too coarse to price them. Where the work is, and why the numbers stay fuzzy.
Read the piece →
Editorial · Comp & negotiation · 43d · Open Label Desk [Editorial]
We pulled the same roles from Glassdoor, Indeed, ZipRecruiter, and Payscale. They disagree with each other by tens of thousands of dollars, and sometimes emit numbers that are simply broken.
Read the piece →
Editorial · CRA life · 43d · Open Label Desk [Editorial]
The updated good clinical practice standard makes centralized monitoring a core pillar. What that means for source verification, site visits, and the future of the road-warrior CRA.
Read the piece →
Editorial · Job moves · 43d · Open Label Desk [Editorial]
Regulatory affairs has its own certification, and unlike most, it is aimed squarely at experienced professionals. What the RAC requires, what it costs, and who it is for.
Read the piece →
Editorial · Job moves · 43d · Open Label Desk [Editorial]
The PMP is a general project management credential, not a clinical one. For clinical trial managers weighing it, here is what it signals, what it costs, and the catch in its pay claims.
Read the piece →
Editorial · Comp & negotiation · 43d · Open Label Desk [Editorial]
Eighteen states now make employers post salary ranges. The research on what that actually did is sobering: pay barely moved, and the ranges got wide enough to be useless.
Read the piece →
Editorial · Industry talk · 43d · Open Label Desk [Editorial]
Most trials miss their enrollment targets, many sites enroll no one, and the delays cost millions a day. The numbers behind the crisis, and why they are a job story.
Read the piece →
Editorial · Job moves · 43d · Open Label Desk [Editorial]
The industry is shifting toward functional service provider staffing, where you work badged inside a sponsor. It offers stability and a narrower job. Know the trade before you take it.
Read the piece →
Editorial · Industry talk · 43d · Open Label Desk [Editorial]
Built from a merger, taken private by a private-equity consortium in 2023, and marked by staff for layoffs ever since. The facts of the ownership, and what its people report.
Read the piece →
Editorial · Industry talk · 43d · Open Label Desk [Editorial]
One of the largest CROs, owned by private equity, and the highest-rated of the mega-CROs by its own staff, though the rating is slipping. The facts and the sentiment, kept separate.
Read the piece →
Editorial · Industry talk · 43d · Open Label Desk [Editorial]
A founder-led, vertically integrated CRO growing fast on paper, and carrying the lowest employee ratings of any major CRO. The facts, the sentiment, and the gap between them.
Read the piece →
Editorial · Comp & negotiation · 43d · Open Label Desk [Editorial]
Every salary figure that says certification pays comes from someone selling the certification. We went looking for independent evidence. There is almost none.
Read the piece →
Editorial · Industry talk · 43d · Open Label Desk [Editorial]
Every conference says trials are going remote. The registry data says decentralization is real but early, concentrated in the wrong places, and reshaping the CRA role rather than ending it.
Read the piece →
Editorial · Industry talk · 43d · Open Label Desk [Editorial]
We pulled every major CRO's employee rating on the same day. The rankings are worth seeing, but the identical complaint running through all of them matters more.
Read the piece →
Editorial · Industry talk · 43d · Open Label Desk [Editorial]
The industry consolidated into a handful of giants through a decade of megadeals. The history is public, and so is the pattern of what happens to staff when the deals close.
Read the piece →
Editorial · Comp & negotiation · 43d · Open Label Desk [Editorial]
Aggregators show contract CRAs earning about the same hourly as salaried ones. The real independent-contractor market runs at nearly double that, and the gap is the whole point.
Read the piece →
Editorial · Industry talk · 43d · Open Label Desk [Editorial]
Venture money and IPOs decide how many trials start, which decides CRO bookings, which decides hiring. Following the funding is following your own job security upstream.
Read the piece →
Editorial · Comp & negotiation · 43d · Open Label Desk [Editorial]
Ask four salary sites what a CRA earns and you get $78,900, $95,000, $100,500, and $113,900. None is wrong. All are useless for the thing you actually need.
Read the piece →
Editorial · Job moves · 43d · Open Label Desk [Editorial]
Two credentialing bodies dominate clinical research, and newcomers waste real money guessing between them. What each certification is, how they differ, and how to choose.
Read the piece →
Editorial · Industry talk · 44d · Open Label Desk [Editorial]
What AI in clinical research actually does in 2026: real workflows, failure rates, FDA and EMA rules, and job impact, written for people who work in trials.
Read the piece →
Editorial · Industry talk · 44d · Open Label Desk [Editorial]
The violations behind clinical warning letters are strikingly consistent year after year. The recurring citations, with real recent examples, and what they say about the work.
Read the piece →
Editorial · Comp & negotiation · 44d · Open Label Desk [Editorial]
Every visa filing carries a government wage level from I to IV. The mix across clinical research reveals how employers classify the jobs, and where they file near the floor.
Read the piece →
Editorial · Job moves · 44d · Open Label Desk [Editorial]
An FDA finding does not just cost remediation. It can make a site un-selectable and an investigator un-hirable. How inspection history follows a career, and how to check it.
Read the piece →
Editorial · Comp & negotiation · 44d · Open Label Desk [Editorial]
The federal filings put regulatory affairs at a middling median but an enormous spread, from the low $80,000s to nearly $200,000. What that range says about the career.
Read the piece →
Editorial · CRA life · 44d · Open Label Desk [Editorial]
Strip the FDA's clinical warning letters down and almost all of them come back to three basics. What they are, real examples of each, and how sites actually lose them.
Read the piece →
Editorial · Comp & negotiation · 44d · Open Label Desk [Editorial]
Among clinical research functions in the federal wage data, drug safety posts the highest median of all. Why the least glamorous corner of the industry pays the best.
Read the piece →
Editorial · Industry talk · 44d · Open Label Desk [Editorial]
The fastest-growing CRO in the group posted a book-to-bill below 1.0, and the market punished it. A lesson in why bookings matter more than the quarter you are in.
Read the piece →
Editorial · CRA life · 44d · Open Label Desk [Editorial]
The government publishes the real wages employers committed to for visa-sponsored roles. Here is how to find what a specific company filed for your title before you negotiate.
Read the piece →
Editorial · Industry talk · 44d · Open Label Desk [Editorial]
The largest CRO on earth is carrying a record backlog and a steady book. A look at what that scale actually signals for hiring, and what it hides.
Read the piece →
Editorial · Industry talk · 44d · Open Label Desk [Editorial]
A quarter of FDA-inspected sponsors draw a citation, and the top finding is failing to monitor trials properly. Read as a labor signal, that is an argument about CRA headcount.
Read the piece →
Editorial · Industry talk · 44d · Open Label Desk [Editorial]
The strongest book-to-bill in the CRO group came with flat revenue and an accounting change. A worked example in reading a headline number the careful way.
Read the piece →
Editorial · Industry talk · 44d · Open Label Desk [Editorial]
The visa filings name the employer on every record. Sorting the clinical research roles by sponsor shows which CROs and sponsors reach overseas to staff the quantitative bench.
Read the piece →
Editorial · Industry talk · 44d · Open Label Desk [Editorial]
Spun off from Labcorp and still posting GAAP losses, Fortrea is booking above 1.1 for the third straight quarter. The bull case, and the caveat, for the people who work there.
Read the piece →
Editorial · Industry talk · 44d · Open Label Desk [Editorial]
Five public CROs, five book-to-bill ratios, one uneven picture. What the latest quarter's bookings say about where clinical research demand is actually heading.
Read the piece →
Editorial · Comp & negotiation · 44d · Open Label Desk [Editorial]
We processed a million federal visa filings to pull the real numbers for biostatistics, statistical programming, and data management. These are wages employers filed with the government.
Read the piece →
Editorial · Comp & negotiation · 44d · Open Label Desk [Editorial]
In a million federal wage filings, biostatisticians appear by the hundreds and CRAs barely at all. That gap is not a data quirk. It tells you something real about the job.
Read the piece →
Editorial · Industry talk · 44d · Open Label Desk [Editorial]
Most of the big CROs are booking more work, yet cost-cutting and restructuring are running at the same time. The gap between a recovering book and a frozen headcount, explained.
Read the piece →
Editorial · Industry talk · 44d · Open Label Desk [Editorial]
The public registry records every trial that gets killed, and why. We read the reasons across thousands of terminated industry trials. Enrollment is the number one killer, and that is a worker story.
Read the piece →
Editorial · Industry talk · 44d · Open Label Desk [Editorial]
Half a million public trial records, and the CROs that do the work are almost invisible in them. The same transparency gap that hides layoffs hides who actually runs your industry.
Read the piece →
Editorial · Industry talk · 44d · Open Label Desk [Editorial]
Not all phases fail at the same rate. The registry shows Phase 2 kills trials more often than any other, and it is also the most common phase. What that means for where you sit.
Read the piece →
Editorial · Comp & negotiation · 44d · Open Label Desk [Editorial]
Cancer trials outnumber the next-largest therapeutic area roughly two to one. Where the trials concentrate is where the specialization, the mobility, and the pay concentrate too.
Read the piece →
Editorial · Job moves · 44d · Open Label Desk [Editorial]
The registry names the sponsor on every trial. Rank the big pharma names by active recruitment and you get a directional map of where the sponsor-side demand is.
Read the piece →
Editorial · CRA life · 44d · Open Label Desk [Editorial]
The same public registry that tracks the whole industry tracks your specific trial. Here is how to read it as an early-warning system for your own job.
Read the piece →